分组1 - Alector reported a quarterly loss of $0.34 per share, better than the Zacks Consensus Estimate of a loss of $0.39, representing an earnings surprise of +13.71% [1] - The company posted revenues of $6.24 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 103.43%, compared to $54.24 million in the same quarter last year [2] - Alector has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times [2] 分组2 - Alector shares have increased by approximately 40.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on $3 million in revenues, and for the current fiscal year, it is -$1.19 on $12 million in revenues [7] - The Medical - Biomedical and Genetics industry, to which Alector belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8]

Core Viewpoint - Arcutis Biotherapeutics, Inc. reported quarterly earnings of $0.13 per share, significantly exceeding the Zacks Consensus Estimate of $0.03 per share, and showing an improvement from a loss of $0.09 per share a year ago, indicating a strong earnings surprise of +290.39% [1] Financial Performance - The company achieved revenues of $129.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 11.93%, and showing a substantial increase from year-ago revenues of $71.36 million [2] - Over the last four quarters, Arcutis Biotherapeutics has consistently exceeded consensus EPS estimates, achieving this four times [2] Stock Performance and Outlook - Despite the positive earnings report, Arcutis Biotherapeutics shares have declined approximately 7.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $94.6 million, while for the current fiscal year, it is $0.38 on revenues of $470.02 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable industry outlook that could positively influence stock performance [8]

Core Viewpoint - Acadia Pharmaceuticals reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, but down from $0.17 per share a year ago, indicating a mixed performance in earnings despite a positive surprise [1][2]. Financial Performance - The company achieved revenues of $283.99 million for the quarter ended December 2025, which fell short of the Zacks Consensus Estimate by 2.94%, compared to $259.6 million in the same quarter last year [2]. - Over the last four quarters, Acadia has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2]. Stock Performance - Acadia shares have declined approximately 7.9% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $268.17 million, and for the current fiscal year, it is $0.68 on revenues of $1.19 billion [7]. - The trend of earnings estimate revisions for Acadia was mixed prior to the earnings release, which may influence future stock movements [6]. Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8].

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +24.11%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.38 per share when it actually produced a loss of $0.36, delivering a surprise of +5.26%.Over the last four quarter ...

Alkermes (ALKS) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $1.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +7.80%. A quarter ago, it was expected that this drugmaker would post earnings of $0.42 per share when it actually produced earnings of $0.49, delivering a surprise of +16.67%.Over the last four quarters, the company has ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Teva Pharmaceutical Industries Ltd. (TEVA) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Teva Pharmaceutical Industries Ltd. is a member of our Medical group, which includes 925 different companies and currently sits at #8 in the Zacks Sector Rank ...

Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to a loss of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.63%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.59 per share when it actually produced a loss of $1.54, delivering a surprise of +3.14%.Over the last four quarters, the comp ...

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -19.98%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.19, delivering a surprise of +32.14%.Over the last four quarters, the ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.64 per share, beating the Zacks Consensus Estimate of $6.62 per share. This compares to earnings of $6.6 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.27%. A quarter ago, it was expected that this drugmaker would post earnings of $5.74 per share when it actually produced earnings of $8.13, delivering a surprise of +41.64%.Over the last four quarters, the c ...

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +219.14%. A quarter ago, it was expected that this company would post earnings of $1.03 per share when it actually produced earnings of $1.67, delivering a surprise of +62.14%.Over the last fou ...